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Preface
These notes are based on lectures given by the first author
in seminars at the Division of Applied Mathematics, Brown University,
at Institut de Recherche D' Inf ormatique et D'Automatique, Rocquencourt,
France, and at Laboratoire de Biochimie Medicale, Hopital Charles Nicolle,
Rouen, France and on an honors project completed at Brown University by
the second named author. Our interest in modeling of the glucose homeo-
static system arose during a joint effort with researchers at Rhode Island
Hospital. In fact, Section 3 of these notes contains a preliminary version
of a model arising from that joint collaboration. We are deeply indebted
to Dr. H. F. Martin and J. Hologgitas and a number of volunteer "subjects"
for their substantial contributions to the work discussed in Section 3.
1. Introduction
One of the most interesting physiological control systems in man
is the one for glucose homeostasis. Proper functioning of this complex
and highly sensitive system is essential for life. Although often
thought of as being mainly involved with carbohydrate metabolism, a
remarkable organ, the liver, provides a means through which protein
metabolism and lipid metabolism play an important role in the glucose
homeostatic system. Even a brief perusal of the section on carbohydrate
metabolism in biochemistry and/or physiology texts will convince one of
the great difficulty in describing this system with a mathematical
model which will at the same time be sufficiently simple so as to allow
validification with in vivo data and sufficiently complex to provide
new insight into the mechanisms involved.
A large number, of organs and hormones [25] (see also Figure 1.1)
play an important role in glucose homeostasis. A secretion of the
P-cells of the pancreas, insulin, has long been recognized as a hypo-
glycemic factor of prime importance. Insulin secretion is thought to
be controlled via signals from the G.I. tract after carbohydrate in-
gestion, in addition to direct stimulus of the p-cells by glucose.
Recent investigations have led to new information on glucagon, a hyper-
glycemic factor secreted by the cc-cells of the pancreas in response to
hypoglycemia. Growth hormone (somatotropin) secreted from the
adenohypophysis (anterior pituitary gland) not only affects glucose
levels in a direct manner, but is believed to interact in a complex
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Figure 1.1
manner with other hormones involved in glucose homeostasis, especially
insulin. Another secretion of the adenohypophysis, ACTH, stimulates
secretion by the adrenal cortex of glucocorticoids (cortisol, etc.)
which also play a role in carbohydrate metabolism.
The major site of action of many of these secretory agents is the
liver, which is essentially an energy exchange and storage organ. For
example, both glucagon and insulin have been implicated in glycogenesis
(synthesis of glycogen, the storage form of carbohydrates), glycogenolysis
(break-down of glycogen to glucose-1-phosphate) and gluconeogenesis
(formation of glucose from non-carbohydrate sources such as glycerol,
lactate, amino acids) through their effects on the level of cAMP
(cyclic adenosine monophosphate), which inhibits glycogen synthetase
and promotes phosphorylation. Another important hormone which affects
(elevates, especially in muscle) the levels of cAMP is epinephrine
(adrenaline), a secretion of the adrenal medulla which is part of an
"emergency" mechanism for quick elevation of plasma glucose in times of
extreme hypoglycemia.
Since a major function of the liver involves gluconeogenesis, it
is clear that any model of carbohydrate metabolism should include in
some way the effect of changing plasma levels of amino acids and free
fatty acids (FFA). Thus the mechanisms for break-down and synthesis of
lipids (lipolysis and lipogenesis) in adipose tissue are important in
any comprehensive modeling attempt. There are other factors, such as
thyroxin, which are also believed to play some role in overall control
of plasma glucose concentration.
In spite of the complexity noted above, there have been
numerous attempts to develop mathematical models for all or parts of
the glucose homeostatic system. In the next section we give a brief
but incomplete survey on these attempts. We make no effort at
describing all previous models, but have tried to make a judicious
choice of models so as to illustrate in our discussions a number of
differing approaches.
Section 3 contains a preliminary version of a model on which we
have been working. Our work is the first, to our knowledge, to offer
a model based on simultaneous in vivo measurement of such a large
number of the variables involved in glucose homeostasis. We recognize
that we still are a long way from a satisfactory model for the physio-
logical control system under discussion here (see the discussions below
on the importance of epinephrine, a catecholamine that we have not yet
been able to include as a dynamic variable in our model). We are,
however, convinced that our approach involving simultaneous in vivo
measurement of all variables deserves emphasis.
2. A Survey of Some Previous Models_
Wrede [Ml] was one of the first to propose a model containing most
of the parameters which are accepted today as having an important role
in the glucose homeostatic system. His goal was a mathematical model,
with emphasis on carbohydrate metabolism during glucose tolerance tests
(GTT), which would be realistic from a physiological standpoint. The
model contained one compartment (plasma) in which variables representing
concentrations of glucose, insulin, glucagon, epinephrine, gluco-
corticoids, thyroxin and growth hormone (x through x respectively)
were to be described dynamically by a set of nonlinear ordinary differ-
ential equations
x.(t) = G.(x1(t),...,x7(t)) + f.(t)
i = 1,2,...,7, where f. are infusion rates. The assumption of only
one compartment implies, of course, that secretion response times and
mixing times are negligible. Assuming that all variables undergo only
small variations about some nominal values, Wrede actually worked with
a linearized version of the above system
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Sxi(t) = _E a^ ox^ t) + aiQ + f.(t)
i = 1,2,...,7, where a.n are basal production rate constants, a.. is
i^
evaluated along constant equilibrium values of the x.'s, and 5x.
is the perturbation of x. from its nominal value. The assumptionj
of small variations is invalid since, for example, the typical
nominal value for glucose concentration is about 80 to 90 mg % while
the concentration varies between approximately 70 to 150 mg % for
normal and between ko and 250 mg $ for abnormal responses during
a standard GTT.
Wrede used a combination of methods to determine numerical
values for the rate constants (coefficients in the system equations)
in his linear model including comparison with previous models,
determination via physiological in vivo rates in experimental
literature, and extrapolation of data from experiments on rat and
dog tissue. The assumptions on his vector model
ox = Aox + ofo + f
are then such that the 7x7 matrix A has the form
A= 0 — 0
so that Xx;,x_, can be solved for as functions of the infusion rates
o> 7
7f>,f . This essentially allows the model to be reduced to a five
b> 7
dimensional vector system. Using Routh's criterion, the author
then establishes stability of the" 5-dimensional model with the
numerical parameter values he has obtained. In fact, he then ob-
tains the roots of the characteristic equation, yielding asymptotic
stability since these all have negative real parts.
Of much greater interest than the stability discussion is
Wrede's analysis of the model with respect to accepted physiological
"facts" of that time. He makes a number of conjectures based on
his study of his model. Some of these, especially those related
to basal production rates, appear to be quite good. A number of
his conjectures about mechanisms that were unknown at the time
have since proved to be quite accurate. A report of simulations
with the model is also included. Some of these curves agree
qualitatively with data curves usually reported for the GTT, while
others are very poor in their approximation to actual responses.
One assumption underlying Wrede's model, that plasma FFA
remains unchanged during responses to glucose ingestion, has for
some time been known to be false. Shames [37] was, to our
knowledge, the first to include plasma FFA levels as an important
aspect of a modeling attempt. However, his goal was not development
of a model to be used in analyzing responses during GTT's, but
instead a theoretical analysis of some of the important variables
(glucose, insulin, FFA) in the glucose regulatory system. His
aim was a quantitative study of mechanisms involved with an eye
8towards a more fruitful laboratory approach to some of the problems
involving the system. He analyzed the dynamic characteristics of
these mechanisms in terms of responses to constant infusions of glucose.
The effects of epinephrine, glucagon, glucocorticoids, thyroxin, and
growth hormone are ignored even though the effects of some of these are
believed to be mediated through FFA, which is a major component of
his study.
One of the most sustained efforts at modeling involving the
system under consideration here has been made by Ackerman, Gatewood,
Rosevear, and Molnar. In a series of publications [1], [2], [20],
[21] they report on attempts at a model in which one or two para-
meters would yield criteria for distinguishing normal individuals
from mild diabetics and prediabetics. Their model is a simplified
one, requiring a limited number of data samples during an oral GTT
and is not aimed at an isomorphic representation of details of the
homeostatic system. We shall give here only a brief summary of
their findings. The basic model contains two variables: G, the blood
glucose concentration, and H, plasma concentration of a fictitious
"composite" hormone (which is to include the action of insulin and
other real hormones). Linearization of a general nonlinear model about
nominal values G ,H leads to non-homogeneous linear equations in
g and h, the variations from the nominal values. That is, one has
g = -m-g - mh + J
h = -nwh +
where g = G - G , h = H-H (see Figure 2.1), and J is the input
function.
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Figure 2.1
Combination of these two first order equations in the usual manner
yields an equation for g of the form
g + 2ag + CDg = S
1 f \ 2where a = 75 (m +JIL); COQ = m^nL + and S = HLJ + J. Solutions to
10
this system, which can be given in- terms of damped oscillations
e~ sin(cot+<t>), to = A\a -to |, and the parameters of S (i.e., j), were
found to agree reasonably well with the damped oscillatory responses
observed in many patients•
The authors studied the system as a function of the parameters
m,,m_,tD and the parameters of J, and compared simulations with data
collected at the Mayo Clinic. In fitting this model to data they found that
although unique values of the parameters could be obtained, variations in
one parameter value could easily be compensated for by variations in the
values of another parameter. Furthermore, the values for a and CD proved
to be highly sensitive to small errors in blood glucose concentrations. How-
ever, they did determine that one parameter, the natural frequency CD , is
relatively insensitive to experimental error and variations in the other model
parameters. Thus they are able to take T = 2ir/CD as the basic description
of responses to the OGTT. Using data from a variety of sources, Ackerman,
et.al. concluded that responses with T substantially less than four hours
are characteristic of normal responses, T substantially larger than h
is indicative of mild diabetes while responses with 3-5 < T < ^ .5
appear to be in a grey area with respect to diagnosis.
The results of these studies are supported by the findings of
Ceresa, et.al. [10] who have taken the same type of two variable model
approach. The main difference between their model and that described
above is their assumption that h actually represents concentrations
of insulin, not a composite hormone. Ackerman, et.al. have pointed out
that simulation studies of the variable h yield a fit to insulin data
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only during the first two to three hours of the five hour OGTT.
Ackerman, Gatewood, Rosevear and Molnar admit that there are a
number of detrimental aspects associated with their two-variable
modeling approach. First, one will never obtain in this way a model
isomorphic in any realistic sense to the physiological control system.
A second difficulty involved inabilities to simulate responses with
biphasic initial peaks. Finally, there were some problems in fitting
the glucose concentration simulations to data in the time period be-
tween three hours and five hours after ingestion. As Ackerman, et.al.
suggest and as our own work reported below establishes, there are other
(hyperglycemic) factors such as glucagon, growth hormone, and perhaps
epinephrine, which play an important role in the control system during
this time period.
Antomonov, et.al. [J] have recently described a model (see
Figure 2.2) based on components consisting of various organs and
sites in the circulatory system, the mechanisms involved in each
component being represented by simple linear ordinary differential
equations. In this three variable model (glucose, insulin,
epinephrine) the authors take a black-box input-output approach
and offer only limited physiological justification in writing the
equations which are detailed below.
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G.I, tract to portal vein:
where rn is the absorption rate from the stomach and intestines into the
portal vein, X. is the characteristic function of A, and y, is the devi-
ation in the portal vein from "normal" or equilibrium glucose concentration y
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Liver;
where i and e are the circulating levels of insulin and epinephrine,
y is the systemic concentration of glucose, and y? is the deviation
in the hepatic vein from the normal glucose concentration.
Pancreas:
where this equation is assumed to hold only when y - y > 0.
Adrenals:
+ a6(y0-y),e - -
where again this holds only in the case y - y < 0. Both this equation
and the previous one obviously assume that there are sensory mechanisms
for the systemic concentration y involved in the controls of the
pancreas and adrenal glands.
Peripherel tissue;
where i, is systemic insulin received by injection into muscle tissue
and y, is the glucose concentration at the tissue output.
Injected insulin;
where i| ' is the rate of resorption due to blood flow from the area
of tissue where the injection was made.
Ill
By solving the above system of equations and fitting the solu-
tions to experimentally obtained curves, the authors determined
values for the parameters a.,b.,c. of the model. They then tested
J u J
the model by simulation of pathology via parameter perturbation.
That is, they asked if one could, by making changes in parameters
appropriate to pathologies, obtain solutions of the model which
simulate responses characteristic of individuals suffering those
pathologies. Some success along these lines is reported in testing
the pancreatic insulin mechanism in the model with regard to diabetes
and insulinemia. Also included are the results on attempts to apply
optimal control theory to choose doses (minimum time criteria) of
glucose and insulin for treatment during pathology. Finally, a study
of the glucose homeostatic system during embryogenesis showed that
evolution of the control mechanism could be paralleled by changing
("evolving") the parameters in the model, the dynamical curves thus
produced by the mathematical model agreeing well with experimental
curves. This, the authors argue, offers substantial support for the
correctness of their model.
An excellent review of some modeling attempts through 196? which
includes comments on the models of Wrede, Shames, and Ackerman, et.al.
described above can be found in [12]. The authors there comment on
the obvious need for nonlinearities in the models (this agrees with our
findings reported in Section 3 below). Such a nonlinear mathematical
model, based on the Ph.D. theses of Charette [11] and Srinivasan [39],
is detailed in [^ 0]. The authors' goal is to reproduce the gross effects
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of metabolic interaction of FFA and glucose in response to TV
infusions of glucose, insulin, etc. A short term (two hours) model
comprised of many interconnected subsystems which have been modeled on
the basis of known stimulus response characteristics is formulated.
The emphasis is on a nonlinear systems approach, with validation of the
model via clinical data available to the authors at the time. An
interesting feature of this model is the extensive use of the hyperbolic
tangent function in connection with switching mechanisms. As the
authors point out [Uo, p. 159], "although the model does not adequately
reproduce the finer details of the actual responses in some instances,
the limited success supports the systems approach to the problem". They
contend that the systems analyst has a role in the development of
knowledge of the physiology of relevant subsystems, contributing to this
effort "by systematizing the known physiologic facts about the
metabolic processes in a consistent mathematical framework, by proposing
to the physiologist specific experiments suggested by model building,
simulation and analysis, and by determining analytically the con-
sequences of conflicting theories on the operation of specific portions
of the overall plant".
We mention one other recent survey paper of interest here. In
[^] Atkins presents a survey of 2^ (some quite different) theoretical
models for regulation of plasma glucose concentration via insulin. The
author's purpose is to "see whether it is valid to propose a model and
fit it to plasma glucose levels only". His conclusion, based on data
fitting and simulation, is that it is impossible to distinguish between
16
and assess the validity of a large number of models when only glucose
data is used to fit the models. This supports fully our own view of
the extreme importance in collecting (simultaneously) data from each
subject for all (or as many as feasible) of the variables involved
during an OGTT.
$. A New Model
In this section we report on a model for glucose homeostasis
being developed "by H. T. Banks and Christin A. Carter of the Division
of Applied Mathematics, Brown University and H. F. Martin and
j. Hologgitas of Rhode Island Hospital. Our goals include a compre-
hensive mathematical model to be used as an aid in teaching and
diagnostic efforts in relation to patients suffering from hormonal
disorders. As with most attempts at modeling, we hope that a systematic
approach based on current physiological information and data from
subjects tested at Rhode Island Hospital will lead to a better under-
standing of the complex physiological control system involved in
homeostasis.
After an overnight fast, subjects were given an oral dose of 100
gms of glucose and required to remain at rest for a five hour period.
Blood samples were taken every twenty minutes in quantities large
enough to permit simultaneous measurement of plasma levels of glucose
(x in the model below), insulin (xp), glucagon (x~), growth hormone
(x7), and free fatty acids (xg). Our initial efforts also included
checks on plasma levels of cortisol (x ), thyroxin (x,-), and amino
acids (xq), bu"t we found that these remain fairly constant during the
five hour test. Thus these quantities are assumed constant in the
model described below.
Our attempts with a linear model were unsuccessful and a pre-
liminary form of the nonlinear model discussed here contains functions
of the following type:
18
0
S(x-a,b) = ) (x-a)/(b-a) a < x < b
1
!
0 x < 0
1 x > 0
1 x < a
Q(x;a,b) = | (b-x)/(b-a) a < x < b
0 x > b
{ (A/a)x 0 < x < aA + m(x-a) x > a
It is obvious that the piecewise linear functions S,Q are meant to
be only rough approximations to the sigmoid curves often found in
saturation-limited phenomena and data. While the actual nonlinearities
are no doubt smoother and more complex, these approximations are ex-
tremely convenient to use when one is running simulations on the
computer while varying the shapes of the curves through variation of
the parameters a and b.
The model, for "normal" responses to the oral glucose tolerance
test (OGTT), is basically a one compartment model (systemic plasma)
although as it will be seen below, we have taken some care in determin-
ing uptake and output terms for the variables in the model at various
organ and tissue sites in the body. We give here each equation of the
model separately along with a brief discussion of underlying assumptions
and justifications.
19
Glucose
;^ ,^) + fjt) + r
The first term on the right side of the equation represents uptake
of glucose by extrahepatic tissue (mainly muscle and adipose tissue)
which is thought to be rate-limited at the cell membrane. Capillary and
interstitial levels of glucose are assumed the same since it is believed
that diffusion rates of glucose across capillary walls into interstitial
fluid are much higher than utilization rates [ 15] . The absence of intra-
cellular free glucose [25, p. 2J8] justifies the assumption that entry
into the cell and not utilization (phosphorylation) is the most important
factor with respect to rate limitation.
It is well-known [25, p. 2J8] that insulin facilitates glucose up-
take in adipose tissue and muscle. In fact, the insulin concentration
of arterial blood has been shown to be the primary factor involved in
stimulation of glucose uptake in intact muscle [13], with the only site
of direct action being the cell membrane [25, p. 2^ 0]. The function L
used above for the action of insulin can be considered an approximation to
a Langmuir type curve. The Langmuir isotherm curve [28 ] is derived
in connection with the adsorption of gases on solids. Extrapolation
of this theory to the attachment of insulin molecules to cell membranes
(concentration of insulin is then equated to gas pressure) involves the
following assumptions t transport of glucose is dependent upon the
number of sites occupied by insulin; there are a limited number of sites;
and insulin facilitates transport only when it is attached to the cell
membrane. That Christensen and 0rskov [13] found a maximum insulin
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effect (at about 200 uU/ml) on muscular glucose uptake lends support
to the above extrapolation. We note that our approximation to the
Langmuir curve is made up of only two linear functions even though in
fact a third function (roughly a constant) should be included for
values of xp larger than about 200 uU/ml. We have not needed to
include this in this preliminary model since our data from normal
subjects to date shows no times at which this level is exceeded.
Insulin levels are not the only limiting factors with regard to
the entry of glucose into extrahepatic cells. Experiments (in vitro
and in vivo) indicate that glucose itself has a stimulatory effect on
muscular glucose uptake [13]. Even if insulin levels do not rise with
an increase in blood glucose, glucose entry will increase due to a
rise in substrate level [25, p. 2J8]. The glucose term incorporated in
our extrahepatic uptake term is saturation limited at both ends. This
simply is indicative of the fact that if glucose blood levels fall too
low, there will be a negligible amount of uptake in muscle and adipose
tissue regardless of the levels of insulin while on the other hand, the
amount of glucose available is no longer considered a limiting factor
when glucose levels are sufficiently high. A simple diffusion term
of the type -ax based on glucose levels (and not involving insulin)
cannot be supported physiologically (see the above comments on diffusion
of glucose across the capillary walls). Furthermore, our attempts to
incorporate a term of this type in the model were not successful when
model simulations were compared with our data.
A third factor which affects significantly the rate of glucose
uptake in extrahepatic tissues is growth hormone, which tends to
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"block" insulin [5], [13], [18], [32], [33], [46]. It is believed
that growth hormone decreases the effectiveness of increased insulin
levels in promoting glucose uptake by decreasing the sensitivity of
muscle and adipose membrane to insulin [33 ]. It may do this either by
interfering with the transport mechanism [25, p. 2^ 2] or perhaps by
decreasing the tissue binding of insulin [19, p. 26l]. An additional or
alternative mode of action is suggested by the report [19, P- 26l] that
growth hormone, in the presence of glucocorticoids, has been found to
elevate plasma levels of protein factors that antagonize the action of
insulin in vitro.
In contrast with the situation in muscle and adipose tissue,
transport across the cell membrane is not the rate limiting factor in
glucose uptake in tissues of the brain, kidney, gastrointestinal tract,
or liver [25, p. 176], [J>k} p. TOO]. Uptake and output in the liver is
quite complicated and will be discussed in detail below. Uptake in the
tissues of the brain, kidney, and G.I. tract appears to be relatively
independent of hormonal variations. In this model we have included
this constant uptake in the term r,. A more realistic approach would
use a function S(x..j cc,P) with a very small and p somewhere be-
tween ho and 60 mg $. This was unnecessary in our work since the
values of x, seldom fall below 60 for subjects with a normal response
to an OGTT.
The liver, the most complex of the organs involved in glucose
homeostasis, is capable of (i) uptake of glucose and its conversion
to glycogen (glycogenesis), (ii) conversion of glycogen to glucose to
be released into the blood (glycogenolysis), and (iii) conversion of
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noncarbohydrate substances such as glycerol, lactate, and amino acids,
to glucose (gluconeogenesis). It is useful (and accurate) to picture
the turnover of glucose by the liver (i.e. glucose to glycogen and
glycogen, etc., to glucose) as constituting a state of "dynamic
equilibrium" in "resting" (i.e. x, unperturbed) situations. That is,
uptake and output by the liver is occurring at a high rate, but is
balanced so that the net effect on blood glucose levels is zero.
Lowered or raised levels of glucose in the blood affect this balance
by changing the rates of uptake and/or output.
One controller of this rate is insulin, which when increased has
the net effect of decreasing output of glucose by the liver [8],
[19, p. 257], [25], [35], [36]. It is believed that insulin achieves
this result by lowering the intracellular levels of cAMP, which is
involved in the metabolism of glucose in at least two important ways.
First of all, cAMP activates phosphorylase kinase kinase which then activates
phosphorylase kinase. This in turn causes the phosphorylation of in-
active glycogen phosphorylase to yield the phosphorylated or active
form. The active form promotes the breakdown of glycogen to glucose-1-
phosphate. Thus, lowering cAMP levels inhibits glycogenolysis and
decreases the direct output of glucose by the liver. A second way in
which cAMP acts in the liver is through the deactivation of glycogen
synthetase. This is effected through the stimulation of glycogen
synthetase kinase which catalyzes the conversion of an active form of
glycogen synthetase to a less active form. Hence decreased intra-
cellular cAMP concentrations lead to reduced inactivation of glycogen
synthetase and an increased rate of glycogenesis.
It has been shown [6], [2h]} [35, p. 326] that insulin also affects
significantly the levels of cAMP in adipose tissue, and to a much
lesser degree, the levels in muscle tissue. As will be discussed
later, insulin thus plays an important role in regulation of lipolysis
in adipose cells. From a modeling point of view, the insulin-mediated
changes in cAMP levels in adipose and muscle cells probably play a
secondary role to the rate-limiting transport at the cell membrane in-
volved in glucose uptake by these tissues (although changing cAMP
levels may play an important role in the transport phenomenon [2U, p.
Therefore, the second term on the right side of the above equation can
be considered as representing the hepatic role for insulin levels with
respect to glucose uptake. Also included in this term is the known
effect of insulin in reducing gluconeogenesis [7], [25, p. 180],
[25, p. 2^ 1] which may also be attributed to a direct action of cAMP or
may simply be secondary to the decreased glycogenolysis since glycogen
depletion accelerates hepatic deamination and transamination reactions
[19, P. 2o8j.
In direct opposition to the effects of insulin on glucose
metabolism in the liver are those of glucagon. Glucagon has been shown
to increase glucose output from the liver by increasing glycogenolysis
and gluconeogenesis [7], [16], [4l] and to decrease glucose uptake by
inhibiting glycogenesis [19, p. 259], [38]• Evidence indicates that
glucagon activates the enzyme adenyl cyclase [24], [25] which is found
in the cell membrane. This enzyme catalyzes the reaction of ATP to
cAMP [25] which acts to increase glycogenolysis, decrease glycogenesis,
and perhaps effect the observed increase in gluconeogenesis (see the
above comments on cAMP and gluconeogenesis). With the possible ex-
ception of myocardium, glucagon does not stimulate muscle glycogenolysis
[25, P. 238]. In fact, its action appears to be limited to the liver.
Growth hormone may also contribute to increased hepatic-glucose
output [19, p. 26l ] although current supporting evidence is far from
conclusive. Attempts at including a term for this action in the model
were not successful when used with our data. One possibility is that
the effects of growth on the liver are delayed as in the case of its
stimulation of lipolysis (see the discussion on the FFA equation
below) so that its effect is not seen in a five hour OGTT.
Another contribution to increased glucose levels involves in-
creased levels of FFA which is related to stimulation of gluconeogenesis.
Two possibilities have been suggested in regard to this stimulation.
The first involves the concomitant release of glycerol with FFA during
lipolysis at fat cells. This glycerol acts as a substrate for gluco-
neogenesis, being converted to phosphoglyceraldehyde which enters the
Embden-Meyeroff pathway for glycolysis [19, p. 202], [25, p. 180]. Thus
increased levels of FFA are indicative of increased levels of glycerol
which are available to play the role of a substrate. The FFA's themselves
may play a direct role in gluconeogenesis by inhibiting pyruvate
oxidation, stimulating pryuvate carboxylation, and promoting malate
formation [^ 2 ].
The role of FFA-stimulated gluconeogenesis is not considered of
major importance during the GTT [19, p. 203 ]• This agrees with our
findings that the FFA term should enter the model only when glucose
levels are relatively low and FFA levels are comparatively high (above
approximately .U mE/,0). In the model we have assumed this effect to be
saturation limited at both ends.
Of the other hormonal controllers involved in glucose regulation,
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epinephrine is the most important. It appears to act in much the same
way as glucagon, although it is effective in muscle and adipose tissues
rather than at the liver [25, p. 177]. Like glucagon, it stimulates
adenyl cyclase which increases the concentration of cAMP, resulting in
the observed increases in glycogenolysis and decreases in glycogenesis
[253j [31]- Epinephrine may also he effective in two other ways: by
directly inhibiting glucose uptake by muscle [31] (in which case it
should be included in the model in the nonhepatic uptake term), and by
stimulating the Cori cycle [25, p. 238], a process involving con-
version of lactate to glucose in the liver.
Epinephrine is normally regarded as an emergency rather than as
a continuous controller in homeostasis [25, p. 2^ 1]. Consequently, it
may not be of great importance during the OGTT. However, evidence in-
dicates that levels of epinephrine may rise dramatically during the
recovery phase of the OGTT response when glucose levels have been
lowered below fasting levels. Unfortunately, no reliable methods have
been developed to measure epinephrine and its effects were by necessity
treated as nonvarying in our model.
Thyroxin is another hormone which plays a role in glucose metabolism,
effecting increased gluconeogenesis in the liver and increased glucose oxi-
dation in tissue [3^ ]. Since thyroxin levels do not change substantially
during the OGTT, this contribution can be included in the constant term r1
in the model.
Experimental evidence indicates that the presence of another group
of hormones, the glucocorticoids, is necessary for the action of glucagon,
epinephrine, and growth hormone in glycogenolysis and gluconeogenesis
[1, P. 673], [25, p. 180], [25, p. 2Ul]. Whether the adrenal cortex and
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its secretions play other than a "permissive" or "conditioner" role in
facilitating glucose metabolism remains uncertain. These effects have
been treated as a constant in the model since plasma levels of the best
known glucocorticoid (cortisol) do not vary significantly during the OGTT.
Two final aspects of the glucose equation remain to be discussed:
the input function f,(t) and a renal clearance term. Relatively
little is known about absorption of materials across the gut so that
modeling of absorption is a significant problem in itself [21].
Based on our limited experience and that of others, we have assumed
an absorption across the gut of approximately 70$ of the total amount
of glucose ingested. The input to the plasma has, to date, been
approximated by a piecewise linear continuous function consisting of
three sequential parts! (i) a steep rise to a maximal absorption rate
(ii) constant maximal absorption and finally (iii) a sharp drop of ab-
sorption to the zero level. T he period of time fpr the sections (i),
(ii), (iii) must naturally vary with the individual subject. A rough
estimate on the ranges of these periods would be about 20-^ 5 minutes.
for phase (i), followed by approximately 1-2 hours of maximum ab-
sorption rate, then a fall to zero by 2 to 3.5 hours after ingestion.
Although most textbooks give figures of approximately 160-180 mg $>
as the renal threshold level for glucose excretion, work and experience
at Rhode Island Hospital indicate that renal excretion will not be a
significant factor unless glucose levels reach approximately 300 mg $>.
This level is never attained by subjects with a normal response to the
OGTT and hence we have not included such a term in our model. Suggested
procedures for the OGTT include collecting urine at the end of the 5
hour OGTT, after having had the patient empty his or her bladder
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immediately prior to the ingestion of the glucose. If an appreciable
amount of sugar is then found in the urine, an S(x • a,|3) term with
a ~ 300 should be included in the model (the other parameters in
this term are chosen so as to be consistent with the total amount of
sugar excretion indicated by the sample).
Insulin
x2(t) = a21(X;L(t) - r21)H(x1(t) - r21) + I21x1(t)H(x1(t) - r21)
Insulin levels in the systemic blood are raised in response to
increased levels of glucose. The feedback effect of blood glucose
levels acting directly on the pancreas [19, p. 257], [3^ , P- 702] is con-
sidered to be the major control of insulin secretion, and is felt by
some to affect insulin release rather than insulin synthesis. However,
there is growing support for the "two-pool" model [25, p. 176] for in-
sulin secretion consisting of (i) rapid release of insulin from a
small "pool" or compartment of the (3-cell and (ii) continuous release
coupled with synthesis. The first term on the right side of the above
equation arises from the assumptions that when glucose levels are
normal or low, secretion of insulin is at a constant low rate (included
as a part of r2). When the level of glucose is elevated above fasting
level, insulin secretion is increased [19, p. 257].
We have also included a term involving the rate of increase of
glucose concentration as a stimulus for insulin secretion. Although
no direct physiological support for this has yet been found, other
authors who have dealt with glucose homeostasis have suspected this
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phenomenon [ Uo] • Work at Rhode Island Hospital supports this type of
term in principle, although no specific in vitro or in vivo experiments
have been performed yet. The "two-pool" theory explained above may
lend some support to this assumption, the rapid release in (i) being
associated with an x-.-type term, while (ii) is modeled by the term
involving levels of x . The mechanism for the rapid-release pool is
not yet completely understood, but may be related to the "glucagon-
like" substance believed to be released by the intestinal tract as an
"early-warning" or pre-hyperglycemia signal to the (3-cells of the
pancreas. While this may not be exactly an x -type signal, sensors of
some type which involve flux of glucose across the intestinal mucosa
appear to be indicated.
In our previous discussion of disappearance of glucose from the
plasma in nonhepatic uptake, we found that the rate-limiting factor
was transport across the cell membrane (hence the complicated term in-
volving insulin, glucose, and growth hormone). In contrast the rate-
limiting factor in the depletion of systemic insulin at extrahepatic
sites appears to be its diffusion from capillaries into interstitial
fluid. In fact, experimental evidence involving adipose cells indicated
a necessity of plasma levels of insulin ten times those needed in
interstitial fluid to produce the actions attributed to insulin [^ 3].
In addition, the liver breaks down and inactivates insulin via the
"insulinase" system. The rate of this degradation also appears to depend
upon circulating insulin levels. We have, therefore, combined hepatic
and nonhepatic "degradation" of insulin in the -a?pXp term.
With the possible exception of epinephrine (which is believed to
act directly on the pancreas to inhibit insulin secretion [19, P- 258]), the
effects of other hormones upon insulin secretion and/or disappearance
remain questionable. Growth hormone interferes with the action of in-
sulin at the cell wall (as noted above, this is not rate-limiting in
the disappearance) but probably has no direct effect on insulin de-
gradation. Secretion may be enhanced, but the mode of action is
unclear since it has not been possible to show a direct in vitro
effect of growth on isolated pancreatic tissue [25, p. 2*4-2]. Glucagon
has been found to stimulate insulin secretion by direct action on the
(3-cells, but its potency has been questioned
Glucagon
Rot much is known concerning the secretion and degradation of
glucagon, the hormone secreted by the a-cells of the pancreas. Only
recently has a reliable method for measuring levels of glucagon in the
blood been developed and there is much current activity on the
mechanics related to this hormone. Even though the theories of linger
and his coworkers [25, p. 2Ul], [30], [Ul] may not yet be widely accepted,
the evidence collected thus far clearly suggests the hypotheses that
hypoglycemia and fasting promote the secretion of glucagon while in-
creased blood glucose levels suppress its secretion. The method of
control is thought to resemble that of insulin; e.g., a sensory
mechanism in the a-cells is triggered directly by stimulation from
circulating glucose and not by neurogenic (CNS) signals [jU, p. J0k~\ .
It is thought that the a-cell is "set" to secrete glucagon at a high
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rate (just as (3-cells are "set" to secrete insulin at low rates)
during the basal fasting state. Increasing glucose levels suppresses
the secretion of glucagon to some minimal rate [^ -1, p. M4-U]. In our
model we have represented this with a term of the form a^ Q(x ) + c,
the constant c being included in the r~, term and being the minimum
level of secretion.
As we have pointed out above, glucagon affects glucose metabolism
at the liver. The observations that circulating glucagon has such a
short half-life (a matter of minutes) [19, p. 259], that a large proportion
of endogenously secreted glucagon is bound in the liver, and that, in
beef liver at least, an enzyme is found which degrades glucagon, in-
dicate that the liver itself helps to regulate the level of glucagon
in the blood. It appears that there is significant degradation of
glucagon based on circulating levels. This is modeled by the second
term on the right in the above equation.
In addition to the component already mentioned, the term r.,
may contain other (known, or as yet unknown) constant factors affecting
the secretion of glucagon. For example, it is already suspected
[25, P- 24l], [30], [4l] that increased levels of amino acids provoke
added glucagon secretion. Since amino acid plasma levels were
relatively unchanged during the OGTT, such an amino acid term would be
included as a part of the r term.
Growth Hormone
x?(t) = a?1i:
The principal controllers of human growth hormone (HGH) levels in
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the systemic blood appear to be the levels of glucose and HGH itself.
During hypoglycemia one usually has an increase in the plasma levels
of HGH [25, p. 242], [45]. It is now thought that lowered levels of
glucose stimulate receptors in the hypothalamus which cause secretion
of a Growth Hormone Releasing Factor (GHRF) to the adenohypophysis,
which then in turn releases HGH into the blood [19, p. 301], [46, p. 76].
In support of such a hypothalmic control mechanism, it has been shown
that infusions of glucose limited to the hypothalamic region prevent
the expected increase in systemic HGH following hypoglycemia [19: 3rd ed.,
p. 333]. Furthermore, both crude and purified extracts of hypothalamic
tissue stimulate the release of HGH from the adenohypophysis [34, p. 686].
Since it is not clear that lowered levels of glucose do anything other
than-signal release of GHRF, we have modeled this strictly as a
triggering term.
A simple secretion based solely on glucose levels alone does not,
however, come close to describing the data collected from subjects at
Rhode Island Hospital. It is likely that secretion of HGH is also
stimulated by falling glucose levels [25, p. 242], [26], [45]; we have
represented this conjecture by the rate term involving x, . Since it
is suspected that the greater the rate of fall, the greater the rise in
HGH secretion [26], we have included x, itself as a proportionality
factor. That this mechanism effects a delayed response (as seen by
observing systemic HGH levels - see also [22, p. 431]) is supported by
our findings with subjects (most had a relatively flat HGH curve until
about 3-5 hours at which time it abruptly rose, approximately .5 to
1.5 hours after a dramatic fall in glucose). This (slightly delayed)
increased secretion is characteristic of the recovery phase [25, p. 242]
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of a response to the OGTT. To explain this phenomenon, we have hy-
pothesized that the rate.of glucose fall is a potent stimulus for
secretion of HGH only when the level of glucose is such that the fall
may lead shortly to frank hypoglycemia. Subjects exhibited significant
drops in glucose levels without an HGH stimulus only in periods where
the level of glucose remained above equilibrium (fasting) levels.
Support for a "negative feedback" mechanism in controlling HGH
levels in the blood is readily available [19, p. 302], [29], [^ 6]. It is
thought that this "feedback" is effected by the pituitary gland itself
through monitoring of HGH plasma concentrations (the hypothalamus is not
implicated here). We have represented this by the last term involving
an "equilibrium" value &„ which is usually approximately 1.0 to
1.5 ng
It is clear that the control system for HGH is more complex then
the ones we have discussed for the hormones secreted by the pancreas.
Thus should not be surprising in light of the fact that the control
system is known to involve at least the CNS, the- hypothalamus, and the
pituitary gland itself. ' . . • • -
Free Fatty Acid
; 032^ 82)
Lipids (fats) are stored in adipose tissue as triglycerides.
These triglycerides are broken down (lipolysis) into glycerol and free
fatty acids which are then free to be transported via' the blood to
other tissues and organs for utilization and conversion. Lipolysis
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is thus the main source of FFA in systemic "blood. It is well-known
that a rise in plasma insulin results in a fall in plasma FFA [22], [23],
this fall being attributed to a decrease in lipolysis [25], [3^ , P- TO2]
caused by an inhibitory effect on a triglyceride lipase [19], [25] in~
volved in the breakdown of TG to FFA and glycerol. This effect of
insulin on the lipase activity of adipose tissue is, in turn, thought
to be a consequence of the reduction of.tissue cAMP concentrations
brought about by increased insulin levels [6], [2^ -], [35] (see the
above discussions on insulin and cAMP). The exact mechanisms by which
cAMP controls lipase activity is not yet known. While the role of
glucagon in enhancing lipolysis is somewhat less established, it appears
that the lipolytic effect of glucagon is also mediated throught its
effect on cAMP levels [6], [19]. Thus we have represented the diametrically
opposed actions of insulin and glucagon by the first two terms in the
equation above.
Studies of the effect of intraveneous insulin administration on
blood glucose and FFA levels have shown that plasma FFA fall is a func-
tion almost exclusively of insulin levels [9, P- 9^1- Thus in the
model we have assumed that any effects that changing glucose concentrations
might have on FFA levels ar.e mediated entirely through insulin.
An increase in growth hormone is believed to produce two effects
on plasma FFA levels', (i) an increased release of FFA into the "blood
due to enhanced lipolysis [25? p. 2^ 2], (ii) a lowering of plasma FFA
due to increased muscle uptake (possibly because of increased fat
oxidation in muscle) [32], [^ 0]. Although both effects are believed
to "be important, the latter is thought to "be an immediate effect, the
former a delayed effect [25], [32], [JJ]. Rabinowitz, et. al. [32]
found that injections of growth hormone in human forearm tissues caused
a prompt increase of FFA in muscle/ an effect which they attributed to
increased muscle oxidation because of an observed drop in respiratory
quotient. Although their explanation has been debated because it has
not been possible to demonstrate accelerated fatty acid oxidation in growth
hormone treated animals [19: 3rd ed., p. 333], it does seem reasonable to
accept their observations of increased uptake. Their work and that of
others [17], [25], [33] reveal a delay of-at least ko minutes before
the increase in lipolysis is observed. This delay is thought to be
related to growth hormone stimulated synthesis of UNA and protein
molecules [17]. Since, for most of our subjects, an increase of growth
was observed only in the last hour of the OGTT, we have neglected this
delayed effect of increased lipolysis in our model. It could be added
to the term above representing increased uptake with little effort.
In addition to insulin, growth hormone, and glucagon, FFA plasma
levels also appear to be affected by epinephrine, thyroxin, and
glueocorticolds'. The stimulating effect of epinephrine on lipase
activity [23], [25] is naturally thought to be a consequence of increased
cAMP tissue concentrations [6]. The inability to include the effects
of epinephrine caused substantial difficulty in attempts to fit our model
to FFA data curves in the period around U hours after ingestion (see
Figure 3.5). One might expect to be unable to attain (with the model) the
observed levels of FFA if one considers the likely possibility of increased
release of epinephrine by the adrenal medulla during the recovery
phase of the OGTT response.
Thyroxin and glucocorticoids are also thought to increase plasma
levels of FFA [23], [27, p. 337], by enhancing lipolysis through their
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effects on levels of a hormone- sensitive lipase [6], [19, p. 22J], [25],
[3^ , P- 70^ ] . Since plasma levels of these hormones remain relatively
constant during the OGTT, their effects are included in the term rg.
Finally, we assume in the model that plasma FFA concentration is
a stimulus for FFA uptake "by liver and muscle for storage and FFA up-
take by the liver for production and release of triglycerides and
ketones .
Numerous simulations varying the parameters in the model have
been carried out on an IBM 360 at Brown University. The results of one
of these simulations is depicted in Figures 3.1 - 3.5 below by the un-
broken lines. A set of data chosen from a representative normal
subject is shown by the cross-marks on these graphs. (Although on this
specific volunteer the quantitative glucagon data points were not all
available, the data curve is, we feel, qualitatively correct in
accordance with our experience with other data sets.) The paramter
values used in the simulations graphed below are as follows:
Glucose:
= 10 a12 = .1
a = ho a = 70
A = 60 a15 = 30
m = .6 p = 90
k o a
=
 5 0
a1? = .5 P18 = -5
PIT = 5 ri = -50
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Insulin:
Growth hormone:
a2i = ^ r21- = 55
T21= 78 • a22= 6
a21 = 1.5 • r2 = 70
Glue agon:
= 200 a = k
= 76 r = 55
= 6 771= 80
= 85 a77=U-5
= .65 e = 1.5
Free fatty acid:
aQ2 = .65 a8? = .76
P82 = 80 P = 18
«83 = 50 r8 = "6
P83 = 65
This preliminary fit leaves room for improvement and it is clear that
much work remains to be done. As more data is collected and the model
is modified and improved, our confidence in it will undoubtedly grow.
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